LNP1892 - A Phase I, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male and Female Subjects
Latest Information Update: 06 Nov 2021
At a glance
- Drugs LNP 1892 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Lupin
- 12 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 17 Jul 2014 New trial record